Cardiothoracic & vascular anesthesia
Effects of esketamine on postoperative negative emotions and early cognitive disorders in patients undergoing non-cardiac thoracic surgery: A randomized controlled trial
Authors' conclusion
A single intraoperative injection of 0.5 mg/kg esketamine can alleviate postoperative anxiety, depression, and pain to some extent. Although cognitive function behavioral evaluation did not show obvious benefits, it can also reduce the production of pro-inflammatory and brain injury-related factors while promoting the generation of brain-derived neurotrophic factor.
Study context
- Population
- Adults undergoing elective non-cardiac thoracic surgery under GA
- Participants
- 129 adults
- Comparison
- Intraoperative esketamine 0.2 mg/kg or 0.5 mg/kg vs placebo
Methodological detailsprospective, single-centre, double-blinded, placebo-controlled
- Prospective
- Single-centre
- Double-blinded
- Placebo-controlled
Primary result
As reported in the abstract
- Significantly lower HADS-A and HADS-D scores in High esketamine vs control on POD1 and POD3
- No significant differences between Low esketamine and control
Further findings
Pain Visual Analogue Scale (VAS) · 2 h and first day after operation
- Lower pain VAS scores in esketamine-treated groups than control
Cognition (Confusion Assessment Method (CAM) and Mini-Mental State Examination (MMSE) scores)
- No significant differences among the three groups
Serum biomarkers · postoperatively
- High esketamine: lower S100β and IL-6, higher BDNF levels
- Serum acetylcholine and norepinephrine not significantly different
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →